Insulet (Nasdaq:PODD) announced today that it reshuffled its organizational structure to accelerate innovation and commercialization.
In connection with the reorganization, Bret Christensen, EVP and chief commercial officer, leaves the company today to pursue other opportunities. He agreed to offer consulting services during a transition period.
Jim Hollingshead, Insulet’s president and CEO, said Christensen “played an integral role” in Insulet’s commercial success during his six-year spell with the company. He most recently played his part in the commercial launch of the next-generation Omnipod 5 automated insulin delivery system.
“[Christensen] helped build a deep, talented commercial team that has contributed to our strong customer base growth, an exceptional customer experience, and differentiated business model and pharmacy channel access,” Hollingshead said. “All of us at Insulet wish Bret well in his next endeavor.”
For the remainder of the structural shift, Insulet intends to implement changes in the second half of the year. It includes new leadership roles, made effective on July 1, 2023.
Get the full story at our sister site, Drug Delivery Business News.